Drug Profile
Dorzolamide/latanoprost - Chong Kun Dang Pharmaceutical
Alternative Names: CKD-351; Latanoprost+D930; Latanoprost/DorzolamideLatest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
- Mechanism of Action Carbonic anhydrase inhibitors; Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Glaucoma
- Discontinued Ocular hypertension
Most Recent Events
- 23 Jan 2023 Discontinued - Phase-III for Ocular hypertension in South Korea before January 2023 (Ophthalmic) (Chong Kun Dang Pharma, January 2023)
- 26 Mar 2021 Phase-III clinical trials in Glaucoma in South Korea (Ophthalmic) before March 2021 (Chong Kun Dang Pharmaceutical's pipeline, March 2021)
- 11 Jun 2020 Phase-II clinical trials in Ocular hypertension in South Korea (Ophthalmic) (NCT04448223) (Chong Kun Dang Pharmaceutical pipeline, July 2020)